1. AB0400 Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: 2-Year Results of A Phase 3 TRIAL of Intravenous Golimumab. (10th June 2014) Authors: Weinblatt, M.E.; Bingham, C.O.; Mendelsohn, A.M.; Kim, L.; Lo, K.H.; Noonan, L.; Baker, D.; Westhovens, R. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 939 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0491 Fatigue is an independent variable predicting physical function and DAS-28 remission for patients with rheumatoid arthritis treated with intravenously administered golimumab: results from phase 3, placebo controlled clinical trial. (23rd January 2014) Authors: Westhovens, R.; Weinblatt, M.E.; Han, C.; Gathany, T.; Kim, L.; Mack, M.; Lu, J.; Baker, D.; Mendelsohn, A.M.; Bingham, C.O. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 665 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders. (12th June 2018) Authors: Crowley, J.; Papp, K.A.; Hong, C.-H.; Parno, J.; Mendelsohn, A.M.; Li, Q.; Cichanowitz, N.; La Rosa, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. (3rd August 2020) Authors: Menter, M.A.; Murakawa, G.J.; Glover, H.; Mendelsohn, A.M.; Parno, J.; Rozzo, S.J.; Davidson, D.; Gupta, A.K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: e803 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. (12th February 2021) Authors: Cantrell, W.; Lee, P.; Mendelsohn, A.M.; Rozzo, S.J.; Liao, W. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 8(2021) Page Start: e526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis. (9th February 2020) Authors: Poulin, Y.; Ramon, M.; Rosoph, L.; Weisman, J.; Mendelsohn, A.M.; Parno, J.; Rozzo, S.J.; Lee, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 7(2020) Page Start: 1500 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). (1st August 2021) Authors: Thaci, D.; Piaserico, S.; Warren, R.B.; Gupta, A.K.; Cantrell, W.; Draelos, Z.; Foley, P.; Igarashi, A.; Langley, R.G.; Asahina, A.; Young, M.; Falqués, M.; Pau‐Charles, I.; Mendelsohn, A.M.; Rozzo, S.J.; Reich, K. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). (4th May 2021) Authors: Thaci, D.; Piaserico, S.; Warren, R.B.; Gupta, A.K.; Cantrell, W.; Draelos, Z.; Foley, P.; Igarashi, A.; Langley, R.G.; Asahina, A.; Young, M.; Falqués, M.; Pau‐Charles, I.; Mendelsohn, A.M.; Rozzo, S.J.; Reich, K. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0169 Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with results observed by 2 weeks: Results of the phase 3, multicenter, double-blind, placebo-controlled trial. (23rd January 2014) Authors: Weinblatt, M.E.; Bingham, C.O.; Mendelsohn, A.M.; Kim, L.; Mack, M.; Lu, J.; Baker, D.; Westhovens, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials. (30th August 2019) Authors: Bissonnette, R.; Fernández‐Peñas, P.; Puig, L.; Mendelsohn, A.M.; Rozzo, S.J.; Menter, A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 1(2020) Page Start: e21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗